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Forty-two defibrillating lead systems for the automatic 
implantable defibrillator were implanted and tested in 
41 patients. Two basic lead configurations were used: 1) 
spring-patch, consisting of a transvenous superior vena 
cava spring electrode as the anode and an apical or left 
lateral ventricular patch electrode (either small [13.9 
cm2] or large [27.9 cm2]) as the cathode; and 2) patch•
patch, consisting of an anterior right ventricular patch 
as the anode and a posterior left ventricular patch as 
the cathode. Of the 42 lead systems, 10 were spring•
patch and 32 were patch-patch combinations. The de•
fibrillation threshold for the patch-patch combinations 
(9.8 ± 6.5 J, mean ± standard deviation) was signifi•
cantly (p < 0.01) lower than that for the spring-patch 
combinations (19.1 ± 10.3 J). Subgroup analysis re•
vealed the lowest defibrillation thresholds for patch-patch 
The automatic implantable defibrillator (AID-B, Intec Sys•
tems) is a device capable of automatically identifying and 
correcting ventricular tachycardia and fibrillation (1-3) and 
has been shown to significantly increase survival in patients 
at high risk for recurrent cardiac arrest (4). The current 
device is a result of an evolutionary development process 
begun by investigators over a decade ago (5-8). 
The defibrillating lead system of the automatic implant•
able defibrillator in the majority of human implants has 
consisted of a trans venous spring electrode (a titanium coil 
with a surface area of 6.5 cm2 ; personal communication, 
S. M. Bach, Jr., MD, Intec Systems) serving as the anode, 
and an apical or left lateral ventricular patch electrode (a 
titanium mesh flat electrode with a surface area of either 
13.9 or 27.9 cm2) serving as the cathode (spring-patch 
configuration) . 
From the Cardiology Division, Department of Medicine, Medical Col•
lege of Wisconsin, Milwaukee, Wisconsin. This study was supported in 
part by grants from the American Heart Association. Milwaukee and the 
Edward Krebs Family, Milwaukee. Manuscript received April 16, 1985; 
revised manuscript received June 25, 1985, accepted July 12. 1985. 
Address for reprints: Paul J. Troup, MD, Cardiology Division, Medical 
College of Wisconsin, 8700 West Wisconsin Avenue, Milwaukee, Wis•
consin 53226. 
© 1985 by the American College of Cardiology 
combinations with at least one large patch. Total surface 
area of defibrillating leads was strongly negatively cor•
related with the defibrillation threshold (p < 0.005). 
Analysis of the relation of clinical variables to defi•
brillation threshold revealed that only amiodarone ther•
apy was independently associated with a significantly 
(p < 0.05) higher defibrillation threshold. Thus, surface 
area of the defibrillating leads is a critical determinant 
of the defibrillation threshold for the implanted defi•
brillator. Patch-patch lead systems with at least one large 
patch may provide an increased safety margin for de•
fibrillation. Conversely, amiodarone therapy is associ•
ated with higher defibrillation thresholds and may de•
crease the margin of safety. 
(J Am Coli Cardiol 1985;6:1315-21) 
It is also possible to use two patch electrodes for defi•
brillation (patch-patch configuration). This configuration is 
obtained by placing one patch posteriorly or posterolaterally 
on the left ventricle, with the second patch positioned an•
teriorly over the right ventricle. Two small patches, two 
large patches or one of each size are possible options for 
the patch-patch configuration. 
It has been reported by Winkle et al. (9) that when reliable 
defibrillation is not obtainable with 25 to 30 J (the output 
of the currently used automatic implantable defibrillator gen•
erator) using the spring-patch configuration, the patch-patch 
configuration may result in lower defibrillation thresholds. 
This report summarizes our experience with various defi•
brillating lead configurations in the first 41 patients undergo•
ing lead implantation at our institution. 
Methods 
Study patients. Forty-one consecutive patients who had 
the lead system of the automatic implantable defibrillator 
implanted were studied. One patient had two lead system 
implants because infection necessitated removal of the first 
system. The defibrillating lead configuration and patient 
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characteristics are shown in Table 1. Thirty-two of the 41 
patients were male and 9 were female, ranging in age from 
13 to 81 years (mean 57.4). 
Thirty-two of the patients had experienced an episode of 
cardiac arrest and nine had symptomatic recurrent sustained 
hypotensive ventricular tachycardia. Thirty-six patients had 
coronary artery disease, three patients had nonischemic 
congestive cardiomyopathy, one patient had hypertrophic 
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nonobstructive cardiomyopathy and one patient had no de•
tectable structural heart disease. The mean left ventricular 
ejection fraction as measured by radionuclide or contrast 
ventriculography was 35.8% (range 13 to 85). 
Operative procedure. General anesthesia was induced 
with a combination of morphine and benzodiazepine. Main•
tenance anesthesia was provided by a combination of nitrous 
oxide and a narcotic (usually fentanyl). The lead system 
Table 1. Patient Data Including Defibrillation Threshold and Defibrillating Lead Configuration in 42 Patients 
Age (yr) L VEF 
Case & Sex Diagnosis (%) 
61M CCM 20 
251M CAD 27 
3 35F CAD 45 
4* 49M CAD 17 
5 58M CAD 25 
6 58M CAD 34 
7 68M CAD 23 
830M HCM 85 
9 50M CAD 50 
10 50M CAD 26 
II 12F CAD 27 
12 13F PED 71 
13 48M CAD 69 
14 57F CAD 37 
15 49M CAD 56 
16 49F CAD 46 
17 57M CAD 33 
18 58M CAD 24 
19 71M CAD 32 
20 68M CAD 34 
21 64M CAD 40 
22 51~ CAD 29 
23 81M CAD 47 
24 57M CAD 25 
25 65M CAD 13 
26 48M CAD 26 
27 66M ASD, CAD 29 
28* 49M CAD 17 
29 59M CAD 30 
30 62F CAD 49 
31 54M CAD 9 
32 12M CAD 24 
33 70F CAD 14 
34 40M CAD 42 
35 48F CCM 30 
36 76M CAD 31 
37 76M CAD 82 
38 58M CAD 36 
39 64M CCM 32 
40 69M CAD 40 
41 59M CAD 51 
42 60M CAD 27 
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*Patients 4 and 28 are the same patient in whom two different lead systems were implanted because of infection of the first leads. An = ventriculotomy 
with subendocardial resection or cryoablation, or both; ASD = atrial septal defect; ASDR = atrial septal defect repair; CA = cardiac arrest; CABO 
= coronary artery bypass grafting; CAD = coronary artery disease; CCM = congestive cardiomyopathy; DFT = defibrillation threshold; F = female; 
HCM = hypertrophic cardiomyopathy; L VEF = left ventricular ejection fraction; M = male; PED = primary electrical disease; PL = large patch 
electrode (27.9 cm2); Ps = small patch electrode (13.9 cm2); Sp = spring electrode; VT '= sustained ventricular tachycardia; + '= taking the drug or 
drugs; - = not taking the drug or drugs. 
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was placed by means of a left anterior thoracotomy in 12 
patients and a median sternotomy in 30 patients. Of the 
latter 30 patients, 29 underwent a surgical procedure in 
addition to lead system placement. Coronary artery bypass 
grafting was performed in 15 patients, bypass grafting in 
conjunction with left ventriculotomy (with subendocardial 
resection or cryoablation, or both) in 12 patients (I of whom 
also underwent repair of a congenital atrial septal defect) 
and left ventriculotomy alone (with subendocardial resection 
or cryoablation, or both) in 2 patients. When other cardiac 
operations were performed, the automatic implantable de•
fibrillator leads were installed and tested after these pro•
cedures had been completed. 
Electrode positioning. In all instances, the placement 
of the electrodes was designed to include the largest mass 
of myocardium possible between them. The initial electrode 
configuration was determined by the operating surgeon on 
the basis of his intraoperative assessment. During the first 
10 implants, a spring-patch configuration was utilized and 
not altered unless unacceptably high defibrillation thresholds 
were obtained. During subsequent implants (partially due 
to experience with difficulty in spring electrode placement 
and migration of several spring electrodes out of position), 
a two patch configuration was elected, again with the size 
of the implanted patches being chosen by the operating 
surgeon. A number of factors influenced the decision re•
garding choosing the patch size, including the location of 
any aortocoronary vein grafts, internal mammary artery grafts 
or ventriculotomy and overall cardiac size. 
When utilized, the spring electrode (the anode of the 
shocking lead system) was introduced through a l4F in•
troducer placed by means of a percutaneous puncture of one 
of the subclavian veins and advanced under fluoroscopic 
guidance to the mid right atrium. In three cases, the spring 
electrode was introduced through the innominate vein when 
technical factors precluded passage from either subclavian 
approach. The patch electrode (cathode of the shocking lead 
system) for the spring-patch configuration was then placed 
over the apical or lateral left ventricle and secured by su•
turing its edges to the ventricular epicardium. When two 
patches were utilized (patch-patch configuration), one was 
sutured to the anterior right ventricular surface (and served 
as the anode) and the other was sutured to the posterior or 
posterolateral left ventricular epicardium (and served as the 
cathode). Two epicardial screw-in electrodes (model K-54, 
Intec Systems) were employed to record e1ectrograms for 
rate counting and synchronization of shocks. In one patient, 
an endocardial rate counting lead was used because of in•
adequate e1ectrographic recordings from the epicardial surface. 
Defibrillation threshold testing. Intraoperative defi•
brillation threshold testing was performed after the lead 
system was installed utilizing an external cardioverter de•
fibrillator (Intec Systems) that delivers a truncated expo•
nential shock waveform (identical to the waveform of the 
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automatic implantable defibrillator pulse generator), with 
adjustable delivered energies from I to 40 J (in increments 
of I J at energy levels between I and 5 J and increments 
of 5 J at energy levels between 5 and 40 1). Ventricular 
fibrillation was induced by brief epicardial application of 
60 Hz. 7.2 V (root mean square) alternating current. The 
shocks were delivered after 5 to 10 seconds of ventricular 
fibrillation. Ventricular fibrillation was defined as a ven•
tricular tachyarrhythmia during which distinct QRS com•
plexes could not be discerned in the surface electrocardio•
graphic leads (I, aVF and V6). 
The initial energy level tested was 20 J. If successful, 
decrements of 5 J were tried until the 5 J level was reached 
or defibrillation was unsuccessful. If 5 J was successful, a 
I J shock was then tested. All unsuccessful attempts were 
followed immediately by a 40 J "rescue" shock, so that 
only one energy level was tested for each episode of ven•
tricular fibrillation. Defibrillation trials were separated from 
one another by intervals of I minute. If the initial 20 J shock 
was unsuccessful, increments of 5 J were tested until de•
fibrillation was achieved. The first unsuccessful shock and 
the lowest successful energy level were then repeated once. 
The defibrillating threshold was defined as the lowest energy 
that terminated ventricular fibrillation. 
Statistical analysis. Unpaired t tests and the one-way 
analysis of variance (10) were used to evaluate the effects 
of several factors on the defibrillation threshold. These fac•
tors were gender, diagnosis, presenting arrhythmia, con•
comitant cardiovascular surgery and treatment with amio•
darone, digoxin or one or more type I antiarrhythmic drugs 
(as defined by Vaughan Williams [ll]). Pearson's corre•
lation was used to evaluate the effects of age, surface area 
of defibrillating leads (total exposed titanium surface of the 
anode plus the cathode) and left ventricular ejection fraction 
(12). Multiple linear regression was then used to extract 
those variables providing independent information regarding 
the defibrillation threshold. All data are expressed as mean 
values ± I SD. 
Results 
Relation of lead configuration to defibrillation thresh•
old. Of the 42 lead systems, 10 were spring-patch (Fig. 1) 
and 32 were patch-patch (Fig. 2) combinations. The mean 
defibrillation threshold for all of the patch-patch combina•
tions (9.8 ± 6.5 J) was significantly (p < 0.01) lower than 
that for the spring-patch configuration (19.1 ± 10.3 1). 
Subgroup analysis based on lead configuration, patch size 
and surface area of the defibrillating leads is shown in Figure 
3. The total surface area of the shocking leads was strongly 
negatively correlated with the defibrillation threshold (p < 
0.005); the larger exposed lead areas yielded the lowest 
defibrillation thresholds. The lowest thresholds were ob-
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Ventricular Patch 
Figure 1. The spring-patch defibrillating lead configuration. A 
transvenous spring electrode (anode) in the superior vena cava and 
an apical patch electrode (cathode) on the anterior surface of the 
left ventricle are utilized for defibrillation. 
tained with patch-patch configurations having at least one 
large patch. 
Influence of clinical variables on defibrillation thresh•
old (Table 2). Amiodarone therapy was associated with a 
significantly (p < 0.05) higher defibrillation threshold. Al•
though patients with cardiomyopathy and those taking dig-
Figure 2. The patch-patch defibrillating lead configuration. An 
anterior right ventricular patch electrode (anode) is paired with a 
posterior left ventricular patch electrode (cathode) for defibrillation. 
Posterior Patch 
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oxin had a higher mean defibrillation threshold, this differ•
ence did not reach statistical significance. Similarly, age, 
presenting arrhythmic event, use of a type I antiarrhythmic 
drug and whether additional cardiac surgery was performed 
had no statistically significant effect on defibrillation thresh•
old. The lower mean defibrillation threshold for the group 
having aneurysmectomy alone was not significantly differ•
ent from the mean defibrillation threshold for patients having 
no additional cardiac surgery. There was also no relation 
between defibrillation threshold and left ventricular ejection 
fraction (r = 0.022, P = NS). Age was negatively cor•
related with defibrillation threshold (r = - 0.364, P < 
0.01). 
Multivariate analysis. When the variables were com•
bined in a multivariate analysis, the surface area of the 
defibrillating leads was most strongly associated with de•
fibrillation threshold (p < 0.01). Amiodarone therapy also 
continued to contribute a significant (p < 0.05) effect on 
the defibrillation threshold. Patient age did not contribute 
any significant additional independent information in this 
analysis. 
Discussion 
Lead configuration and defibrillation threshold. The 
implanted defibrillator was initially conceived as a totally 
transvenous device utilizing a catheter electrode system (13). 
Subsequently, it was shown in dogs that the most consistent 
and lowest energy requirements for defibrillation were 
achieved with patch electrodes placed on the base and apex 
of the heart (6,14). A superior vena cava spring electrode 
with an apical patch electrode was found to be almost as 
effective and functioned well in a chronic dog model (IS), 
and was then adopted for the initial human implants (I). 
Our data indicate that the surface area of the defibrillating 
leads is one critical determinant of the energy required to 
achieve defibrillation. Defibrillation relates to the delivery 
of a current density adequate to depolarize a critical mass 
of myocardium (16). In studies of transthoracic defibrilla•
tion, it has been shown in dogs that larger electrode paddles 
improved the success rate of ventricular defibrillation (17), 
possibly related to a lower transthoracic impedance with 
larger electrode paddles (18,19). Electrode surface area may 
become excessive, however, resulting in more extracardiac 
currentftow, with inadequate current density delivered to 
the heart for defibrillation (20). An analogous situation may 
well exist with implanted defibrillating electrode systems. 
Patch systems that are excessively large may lead to "shunt•
ing" of current between the edges of the electrodes instead 
of through the intervening myocardium. Optimal electrode 
size for the implanted shocking leads has not been defined 
and, in fact, will probably need to be individualized. As a 
practical matter, because the automatic implantable defi•
brillator has a finite delivered energy in the range of 25 to 
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Figure 3. Relation of defibrillation thresh•
old (OFT) to the surface area of the defi•
brillating leads (exposed titanium of the an•
ode plus cathode). Data points (expressed as 
mean ± I standard deviation) are shown for 
each lead configuration and expressed nu•
merically below. The solid line (y = - O.342x 
+ 26.6) is the least squares line for the data 
points. PL == large patch electrode (27.9 cm2); 
P, = small patch electrode (13.9 cm2); 
Sp = spring electrode. 
DFT(joules) 
40 
30 
20 
10 
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35 J, factors that reduce the threshold for defibrillation will 
increase the margin of safety, Our data strongly suggest that 
one means of reducing the defibrillation energy requirement 
is the implantation of a two patch electrode system and that, 
preferably, the system should include at least one large 
patch. 
Effect of antiarrhythmic agents on defibrillation 
threshold. Amiodarone therapy was associated with a sig•
nificantly higher defibriIlation threshold independent of the 
surface area of the defibrillating leads or any other variable 
analyzed, Therefore, if a patient with an implanted defi•
brillator is started on amiodarone therapy, repeat testing is 
mandatory to ensure that the device is still capable of achiev•
ing defibrillation. Conversely, if a patient already taking 
10 20 30 40 50 60 70 80 
SURFACE AREA (cm2) 
( Anode + Cathode) 
amiodarone has a relatively high defibrillation threshold, 
discontinuing the drug may lower the threshold to a more 
acceptable level. Amiodarone-induced refractoriness to car•
dioversion (using the implanted defibrillator lead system) 
has been reported by Fogoros (21) in a patient in whom a 
40 J shock delivered through the implanted leads was un•
successful in terminating ventricular fibrillation while the 
patient was receiving amiodarone therapy. After discontin•
uation of amiodarone for 3 months, defibrillation was ac•
complished with 10 J. 
The role of other antiarrhythmic agents in this context 
is not well defined. In the current study, no significant re•
lation was found between either digoxin therapy or type I 
antiarrhythmic drug therapy and defibrillation threshold (al-
Table 2. Influence of Clinical Variables on Defibrillation Threshold 
Variable Mean DFT p Value 
Sex M 11.9 NS 
F 12.8 
Diagnosis CAD 10.8 NS 
CM 18.8 
Arrhythmic event CA 12.3 NS 
VT 11.3 
Other cardiac surgery None 14.3 NS 
An 6.0 
None 14.3 NS 
CABG 11.3 
None 14.3 NS 
An. CABG 10.2 
Amiodarone (+) 15.1 < 0.05 
(-) 90 
Digoxin (+) 13.7 NS 
(-) 10.2 
Type [ drug (+) 12.6 NS 
(-) 11.4 
CM = cardiomyopathy; NS = not significant; other abbreviations as in Table I. 
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though it should be noted that the statistical analysis did not 
address individual type I antiarrhythmic agents due to the 
multiplicity of single agents employed). This is in agreement 
with data from animal experiments (22) suggesting that there 
is no acute change in defibrillation threshold with digoxin 
or procainamide (administered by intravenous bolus) using 
the automatic implantable defibrillator lead system. How•
ever, several type I antiarrhythmic drugs (lidocaine, phe•
nytoin and quinidine) have been reported (23,24) to raise 
transthoracic ventricular defibrillation thresholds in dogs. 
In contrast, bretylium and clofilium have been shown to 
decrease the canine transthoracic ventricular defibrillation 
threshold (25), an effect with potential benefit in patients 
with implanted defibrillators. The effects of antiarrhythmic 
and other drugs on defibrillation thresholds with implanted 
lead systems is ih need of further investigation. 
Limitations of the study. The clinical determination of 
the defibrillation threshold as a single quantity of energy, 
implying a sharp distinction between effective and ineffec•
tive energy levels, is probably a misleading concept. It has 
been shown in dogs that there is a range of energies that 
are more or less successful in producing defibrillation (26). 
During our initial implantation experience, it was not clear 
how well defibrillation threshold testing would be tolerated 
by patients. Therefore, we elected to minimize the number 
of fibrillation-defibrillation trials. We have, however, noted 
no untoward effects from the defibrillation trials. Similarly, 
it would have been informative to test every lead configu•
ration in every patient (which would have allowed the patient 
to serve as his or her own control). Once a satisfactory lead 
configuration was found, however, we elected not to con•
duct trials of other lead configurations to minimize the po•
tential for patient morbidity. Additionally, it should be noted 
that random selection of energies for the defibrillation trials 
might have given additional information regarding the effect 
of time and previous shocks on the efficacy of subsequent 
shocks since in our present protocol, lower energy shocks 
Were delivered only after successful higher energy shocks. 
The data reported are specific to the lead systems and 
the truncated exponential waveform utilized by the Intec 
device. Extrapolation of these results to other defibrillation 
waveforms is not possible. 
Conclusions. There is a significant relation between de•
fibrillating lead configuration and defibrillation threshoid for 
the automatic implantable defibrillator. Specifically, it ap•
pears that lead surface area is a critical determinant. Patch•
patch lead systems with at least one large patch were as•
sociated with the lowest defibrillation thresholds and may 
provide a larger margin of safety for defibrillation. Addi•
tionally, amiodarone therapy was associated with signifi•
cantly higher defibrillation thresholds. Therefore, defibril•
lation testing should be repeated if amiodarone therapy is 
initiated after defibrillator implantation to ensure continued 
efficacy. Because the time course of amiodarone effect on 
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defibrillation threshold is unknown, the. timing of repeat 
testing is empiric and we select an arbitrary time 4 to 6 
weeks after initiation ot the drug. Recommendat~ons re•
garding other antiarrhythmic agents await further delineation 
of their role in modulating the defibrillation threshold. 
We thank Deanna Andre, Sharon Duquette, RN and Jan Veseth-Rogers, 
RN for their invaluable assistance in the collection of patient data; Raymond 
G. Hoffmann, PhD for preparing the statistical anaiysis and Donna Weitzer 
for preparing the manuscript. 
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